Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis

• Inge Stegeman ,

  * E-mail: i.stegeman@umcutrecht.nl

  Affiliations Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands, Department of Otorhinolaryngology—Head and Neck Surgery, University Medical Center Utrecht, Utrecht, The Netherlands

  ⨯
• Patrick M. Bossuyt,

  Affiliation Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands

  ⨯
• Tsung Yu,

  Affiliation Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America

  ⨯
• Cynthia Boyd,

  Affiliation School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Milo A. Puhan

  Affiliations Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

  ⨯